Enantioselective LC/ESI-MS/MS Analysis and Pharmacokinetic and Tissue Distribution Study of (2RS)-1-(7-Methoxy-1H-indol-4-yloxy)-3-(2-(2-methoxyphenoxy)ethylamino)-propan-2-ol in Rats

被引:3
|
作者
Walczak, Maria [1 ]
Szymura-Oleksia, Joanna [1 ]
Groszek, Grazyna [2 ]
机构
[1] Jagiellonian Univ, Coll Med, Dept Pharmacokinet & Phys Pharm, PL-30688 Krakow, Poland
[2] Rzeszow Univ Technol, Fac Chem, Dept Ind & Mat Chem, Rzeszow, Poland
关键词
stereoselectivity; derivatization; aminopropan-2-ol; pharmacokinetics; in vivo; PERFORMANCE LIQUID-CHROMATOGRAPHY; STEREOSELECTIVE ANALYSIS; BETA-BLOCKERS; HUMAN PLASMA; PHARMACODYNAMICS; CARVEDILOL; ENANTIOMERS;
D O I
10.1002/chir.22011
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A sensitive and stereospecific liquid chromatography-tandem mass spectrometry method for the quantitative determination of TWo8 enantiomers ((2RS)-1-(7-methoxy-1H-indol-4-yloxy)-3-(2-(2-methoxyphenoxy)ethylamino)-propan-2-ol) was developed and validated in rat serum and some tissues. Racemic TWo8 is a new chemical entity, and it has been shown to possess pharmacological activity in vivo. The assay involved the diastereomeric derivatization of racemic TWo8 with 2,3,4,6-tetra-O-acetyl-beta-glucopyranosyl isothiocyanate. The TWo8 diastereoisomers quantification was performed on a triple quadrupole mass spectrometer employing an electrospray ionization technique. The precursor to the product ion transition for TWo8 derivatives and for the internal standard (carbamazepine) was m/z 776.4???387.2 and 237.4???194.4, respectively. The assay was validated with a linear range of 102000?ng/ml of racemic TWo8. The inter-day precisions for (-)-(S)-TWo8 and (+)-(R)-TWo8 were 2.1% to 14.9% and 1.3% to 14.8%, respectively. The inter-day accuracy for (-)-(S)-TWo8 and (+)-(R)-TWo8 was within 86% to 114% and 91% to 114%, respectively. A pilot pharmacokinetic study of this new beta-adrenolytic compound has shown that (-)-(S)-TWo8 is eliminated faster than its antipode. The terminal half-lives of (-)-(S)-TWo8 and (+)-(R)-TWo8 were 3.2 and 3.9?h, respectively. The compound distribution into different organs, evaluated in tissue homogenate samples following TWo8 intravenous administration, showed an enantioselective penetration of TWo8 enantiomers in the liver (p?<?0.03), in the kidney (p?<?0.001), and in the lungs (p?<?0.05). The developed method using liquid chromatography-tandem mass spectrometry method with electrospray ionization could be employed for quantitative determination of compounds with similar structure. Chirality 24:591599, 2012. (c) 2012 Wiley Periodicals, Inc.
引用
收藏
页码:591 / 599
页数:9
相关论文
共 50 条
  • [41] Synthesis of deuterium-labeled 1-(4-methoxybenzyl)-3-(5-nitrothiazol-2-yl)urea (AR-A014418) as an internal standard for LC–MS analysis
    Dawei Liang
    Yueqiu Wang
    Tingchang Yan
    Zhaoyang Wang
    Journal of Radioanalytical and Nuclear Chemistry, 2020, 325 : 217 - 222
  • [42] FT-IR and FT-Raman investigation, quantum chemical studies, molecular docking study and antimicrobial activity studies on novel bioactive drug of 1-(2,4-Dichlorobenzyl)-3-[2-(3-(4-chlorophenyl)-5-(4-(propan-2-yl)phenyl-4,5-dihydro-1H-pyrazol-1-yl]-4-oxo-4,5-dihydro-1,3-thiazol-5(4H)-ylidence]-2,3-dihydro-1H-indol-2-one
    Viji, A.
    Balachandran, V
    Babiyana, S.
    Narayana, B.
    Salian, Vinutha V.
    JOURNAL OF MOLECULAR STRUCTURE, 2020, 1215 (1215)
  • [43] Enhancing analysis throughput, sensitivity and specificity in LC/ESI-MS/MS assay of plasma 25-hydroxyvitamin D3 by derivatization with triplex 4-(4-dimethylaminophenyl)-1,2,4-triazoline-3,5-dione (DAPTAD) isotopologues
    Ogawa, Shoujiro
    Kittaka, Hiroki
    Nakata, Akiho
    Komatsu, Kenji
    Sugiura, Takahiro
    Satoh, Mamoru
    Nomura, Fumio
    Higashi, Tatsuya
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2017, 136 : 126 - 133
  • [44] Synthesis of deuterium-labeled 1-(4-methoxybenzyl)-3-(5-nitrothiazol-2-yl)urea (AR-A014418) as an internal standard for LC-MS analysis
    Liang, Dawei
    Wang, Yueqiu
    Yan, Tingchang
    Wang, Zhaoyang
    JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY, 2020, 325 (01) : 217 - 222
  • [45] Comprehensive Comparisons between 1-Phenyl-3-methyl-5-pyrazolones, 1-(4-Methoxyphenyl)-3-methyl-5-pyrazolones and 1-(2-Naphthyl)-3-methyl-5-pyrazolones as Labeling Reagents Used in LC-DAD-ESI-MS-MS Analysis of Neutral Aldoses and Uronic Acids
    Zhiwei Sun
    Cuihua Song
    Lian Xia
    Xiaoyan Wang
    Yourui Suo
    Jinmao You
    Chromatographia, 2010, 71 : 789 - 797
  • [46] Comprehensive Comparisons between 1-Phenyl-3-methyl-5-pyrazolones, 1-(4-Methoxyphenyl)-3-methyl-5-pyrazolones and 1-(2-Naphthyl)-3-methyl-5-pyrazolones as Labeling Reagents Used in LC-DAD-ESI-MS-MS Analysis of Neutral Aldoses and Uronic Acids
    Sun, Zhiwei
    Song, Cuihua
    Xia, Lian
    Wang, Xiaoyan
    Suo, Yourui
    You, Jinmao
    CHROMATOGRAPHIA, 2010, 71 (9-10) : 789 - 797
  • [47] Condensation of 2-(4-chlorophenyl)-1-(2,4-dihydroxyphenyl)ethanone with N,N-dimethylformamide dimethyl acetal: an effective approach to 3-(4-chlorophenyl)-7-methoxy-4H-chromen-4-one, N,O- and N,N-heterocycles
    Moskvina, Viktoriia S.
    Shilin, Sergey V.
    Khilya, Volodymir P.
    CHEMISTRY OF HETEROCYCLIC COMPOUNDS, 2015, 51 (09) : 799 - 803
  • [48] Condensation of 2-(4-chlorophenyl)-1-(2,4-dihydroxyphenyl) ethanone with N,N-dimethylformamide dimethyl acetal: an effective approach to 3-(4-chlorophenyl)-7-methoxy-4H-chromen-4-one, N,O- and N,N-heterocycles
    Viktoriia S. Moskvina
    Sergey V. Shilin
    Volodymir P. Khilya
    Chemistry of Heterocyclic Compounds, 2015, 51 : 799 - 803
  • [49] Development of LC/MS/MS assay for the determination of 5-ethyl-2-{5-[4-(2-hydroxyethyl)piperazine-1-sulfonyl]-2-propoxyphenyl}-7-propyl-3,5-dihydropyrrolo[3,2-d]pyrimidin-4-one (SK3530) in human plasma:: application to a clinical pharmacokinetic study
    Shin, Beom Soo
    Hu, Seul Ki
    Kim, John
    Oh, Joon Gyo
    Youn, Won-No
    Lee, Bongyong
    Um, Key An
    Kim, Dae-Kee
    Lee, Ju Young
    Yoo, Sun Dong
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2007, 45 (01) : 176 - 184
  • [50] Preclinical absorption, distribution, metabolism, excretion, and pharmacokinetic--pharmacodynamic modelling of N-(4-(3-((3S,4R)-1-ethyl-3-fluoropiperidine-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-4-yloxy)-3-fluorophenyl)-2-(4-fluorophenyl)-3-oxo-2,3-dihydropyridazine-4-carboxamide, a novel MET kinase inhibitor
    Liederer, Bianca M.
    Berezhkovskiy, Leonid M.
    Dean, Brian J.
    Dinkel, Vikki
    Peng, Jing
    Merchant, Mark
    Plise, Emile G.
    Wong, Harvey
    Liu, Xingrong
    XENOBIOTICA, 2011, 41 (04) : 327 - 339